Metastatic disease from uveal melanoma: treatment options and future prospects.
Metastatic disease from uveal melanoma: treatment options and future prospects.
复制标题
紫veal瘤的转移性疾病：治疗选择和未来前景。
DOI：
10.1136/bjophthalmol-2016-309034
复制
发表时间：
2017-01
期刊：
影响因子：
--
通讯作者：
Nathan PD
中科院分区：
文献类型：
--
作者：
Carvajal RD;Schwartz GK;Tezel T;Marr B;Francis JH;Nathan PD
葡萄膜黑色素瘤占所有眼部黑色素瘤的约85%，高达50%的患者发展为转移性疾病。转移最常局限于肝脏，由于很少有患者适合进行可能治愈的手术，因此预后较差。目前发表的关于转移性葡萄膜黑色素瘤的最佳管理和治疗的证据很少，在这种情况下缺乏有效的治疗方法，导致皮肤黑色素瘤患者广泛使用全身治疗。葡萄膜黑色素瘤和皮肤黑色素瘤本质上是不同的疾病，因此需要专门的管理策略和治疗葡萄膜黑色素瘤。这篇综述探讨了葡萄膜黑色素瘤的生物学，以及这与转移性疾病中正在进行的靶向治疗试验的关系。此外，我们考虑优化患者管理和护理的选择。
Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localised to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed. This review explores the biology of uveal melanoma and how this relates to ongoing trials of targeted therapies in the metastatic disease setting. In addition, we consider the options to optimise patient management and care.